{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T20:58:41Z","timestamp":1791752321846,"version":"4.3.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T00:00:00Z","timestamp":1329177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI 5U19CA079689"],"award-info":[{"award-number":["NCI 5U19CA079689"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U19CA79689"],"award-info":[{"award-number":["U19CA79689"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Evidence-based treatment guidelines recommend low molecular weight heparin (LMWH) monotherapy for cancer-associated venous thromboembolism (VTE). This analysis assessed the first-line treatment strategies for VTE in patients with advanced solid tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>Using administrative data from advanced lung, prostate, colon, or breast cancer patients diagnosed between January 2000 and December 2007 at four HMOs with integrated delivery systems, patients with an inpatient or outpatient VTE diagnosed within 2 years after cancer diagnosis and an outpatient purchase of warfarin, LMWH, and\/or fondaparinux anticoagulant within 7 days of the VTE diagnosis were identified. First-line outpatient VTE pharmacological treatment and factors independently associated with receipt\/non-receipt of LMWH monotherapy were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Overall, 25% of the 1,089 eligible patients received LMWH monotherapy as primary VTE treatment. The percentage increased steadily over time from 18% among patients diagnosed in 2000 to 31% among those diagnosed in 2007. Factors associated with LMWH monotherapy included VTE diagnosis year, chemotherapy within 60 days prior to VTE diagnosis, history of VTE prior to cancer diagnosis, and invasive surgery in the 90 days following VTE diagnosis. Colorectal and prostate cancer patients versus lung cancer patients and stage III versus stage IV patients were less likely to be treated with LMWH monotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions.<\/jats:title>\n                  <jats:p>Adoption of LMWH monotherapy as initial treatment for cancer-associated VTE was low but increased steadily over the study period. Future studies should explore reasons underlying the underutilization of this preferred evidence-based treatment as well as the comparative effectiveness of LMWH versus warfarin-based anticoagulation in real-world cancer patients with VTE.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2011-0323","type":"journal-article","created":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T04:52:52Z","timestamp":1329281572000},"page":"419-427","source":"Crossref","is-referenced-by-count":44,"title":["Outpatient Use of Low Molecular Weight Heparin Monotherapy for First-Line Treatment of Venous Thromboembolism in Advanced Cancer"],"prefix":"10.1093","volume":"17","author":[{"given":"Thomas","family":"Delate","sequence":"first","affiliation":[{"name":"a Clinical Pharmacy Research, Kaiser Permanente Colorado, Aurora, Colorado, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Witt","sequence":"additional","affiliation":[{"name":"a Clinical Pharmacy Research, Kaiser Permanente Colorado, Aurora, Colorado, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Ritzwoller","sequence":"additional","affiliation":[{"name":"b Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C.","family":"Weeks","sequence":"additional","affiliation":[{"name":"c Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Kushi","sequence":"additional","affiliation":[{"name":"d Division of Research, Kaiser Permanente Northern California, Oakland, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Hornbrook","sequence":"additional","affiliation":[{"name":"e The Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin J.","family":"Aiello Bowles","sequence":"additional","affiliation":[{"name":"f Group Health Research Institute, Group Health Cooperative, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Schrag","sequence":"additional","affiliation":[{"name":"c Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,2,14]]},"reference":[{"key":"2021122308245514700_B1","first-page":"654","volume-title":"Phlegmasia alba dolens, Clinique medicale de l'Hotel-Dieu de Paris, 3","author":"Trousseau","year":"1865"},{"key":"2021122308245514700_B2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/bmj.302.6778.709","article-title":"Incidence of venous thromboembolism verified by necropsy over 30 years","volume":"302","author":"Lindblad","year":"1991","journal-title":"BMJ"},{"key":"2021122308245514700_B3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-2007-994915","article-title":"The thrombophilic state induced by therapeutic agents in cancer patient","volume":"25","author":"Lee","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"2021122308245514700_B4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122308245514700_B5","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"key":"2021122308245514700_B6","doi-asserted-by":"crossref","first-page":"401S","DOI":"10.1378\/chest.126.3_suppl.401S","article-title":"Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"B\u00fcller","year":"2004","journal-title":"Chest"},{"key":"2021122308245514700_B7","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","article-title":"; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer","volume":"25","author":"Lyman","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308245514700_B8","volume-title":"Practice Guidelines in Oncology-v. 1.2010: Venous thromboembolism disease","author":"National Comprehensive Cancer Network"},{"key":"2021122308245514700_B9","first-page":"CD006649","article-title":"Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer","volume":"6","author":"Akl","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122308245514700_B10","first-page":"pii","article-title":"Thromboembolism","author":"McManus","year":"2011","journal-title":"Clin Evid"},{"key":"2021122308245514700_B11","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1111\/j.1538-7836.2006.02073.x","article-title":"Barriers to long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis","volume":"4","author":"Wittkowsky","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2021122308245514700_B12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3324\/haematol.11458","article-title":"Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry","volume":"93","author":"Imberti","year":"2008","journal-title":"Haematologica"},{"key":"2021122308245514700_B13","first-page":"12","article-title":"Building a virtual cancer research organization","volume-title":"J Natl Cancer Inst Monogr","author":"Hornbrook","year":"2005"},{"key":"2021122308245514700_B14","first-page":"326","article-title":"The validity of ICD-9-CM codes in identifying postoperative deep vein thrombosis and pulmonary embolism","volume":"33","author":"Zhan","year":"2007","journal-title":"Jt Comm J Qual Patient Saf"},{"key":"2021122308245514700_B15","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"2021122308245514700_B16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(08)60202-0","article-title":"Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study","volume":"371","author":"Cohen","year":"2008","journal-title":"Lancet"},{"key":"2021122308245514700_B17","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1378\/chest.127.5.1515","article-title":"Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy","volume":"127","author":"Witt","year":"2005","journal-title":"Chest"},{"issue":"suppl 1","key":"2021122308245514700_B18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1055\/s-2000-9499","article-title":"Low-molecular-weight heparin and cancer","volume":"26","author":"Zacharski","year":"2000","journal-title":"Semin Thromb Hemost"},{"key":"2021122308245514700_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-125-1-199607010-00001","article-title":"The long-term clinical course of acute deep venous thrombosis","volume":"125","author":"Prandoni","year":"1996","journal-title":"Ann Intern Med"},{"key":"2021122308245514700_B20","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1200\/JCO.2003.02.042","article-title":"Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?","volume":"21","author":"Masci","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122308245514700_B21","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s11239-008-0210-5","article-title":"A descriptive evaluation of warfarin use in patients receiving hospice or palliative care services","volume":"27","author":"Hill","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"2021122308245514700_B22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/bmj.38733.616065.802","article-title":"Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study","volume":"332","author":"Noble","year":"2006","journal-title":"BMJ"},{"key":"2021122308245514700_B23","first-page":"126","article-title":"Diagnosis of venous thromboembolic disease in cancer patients","volume":"17","author":"Gomes","year":"2003","journal-title":"Oncology (Williston Park)"},{"key":"2021122308245514700_B24","doi-asserted-by":"crossref","first-page":"955","DOI":"10.7326\/0003-4819-137-12-200212170-00008","article-title":"Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism","volume":"137","author":"Prandoni","year":"2002","journal-title":"Ann Intern Med"},{"key":"2021122308245514700_B25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/archinte.159.5.457","article-title":"Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism","volume":"159","author":"Kuijer","year":"1999","journal-title":"Arch Intern Med"},{"key":"2021122308245514700_B26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/ATVBAHA.108.182428","article-title":"Venous thromboembolism: risk factors for recurrence","volume":"29","author":"Zhu","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2021122308245514700_B27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/pds.2061","article-title":"Determining the test characteristics of claims-based diagnostic codes for the diagnosis of venous thromboembolism in a medical service claims database","volume":"20","author":"Tagalakis","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2011-0323","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0323","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/3\/419\/41870666\/oncolo_17_3_419.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/3\/419\/41870666\/oncolo_17_3_419.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T22:36:02Z","timestamp":1640298962000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/3\/419\/6403242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,14]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,2,14]]},"published-print":{"date-parts":[[2012,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0323","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,3,1]]},"published":{"date-parts":[[2012,2,14]]}}}